BAILLIE GIFFORD & CO 13D and 13G filings for Rubius Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-03 11:28 am Sale | 2023-02-28 | 13G | Rubius Therapeutics, Inc. RUBY | BAILLIE GIFFORD & CO | 0 0.000% | -4,869,126 (Position Closed) | Filing |
| 2023-01-20 07:32 am Sale | 2022-12-30 | 13G | Rubius Therapeutics, Inc. RUBY | BAILLIE GIFFORD & CO | 4,869,126 5.390% | -61,733 (-1.25%) | Filing |
| 2022-01-26 06:55 am Purchase | 2021-12-31 | 13G | Rubius Therapeutics, Inc. RUBY | BAILLIE GIFFORD & CO | 4,930,859 5.490% | 220,798 (+4.69%) | Filing |
| 2021-01-27 12:12 pm Purchase | 2020-12-31 | 13G | Rubius Therapeutics, Inc. RUBY | BAILLIE GIFFORD & CO | 4,710,061 5.820% | 458,591 (+10.79%) | Filing |